Schizophrenia
Conditions
Keywords
Acute psychotic episode of Schizophrenia
Brief summary
The primary objective of this Non- Interventional Study (NIS) is to describe the use of atypical antipsychotics in subjects with Schizophrenia during the hospitalisation due to acute psychotic episode by evaluation of drug, dose and mode of administration of the medication.
Detailed description
RECONNECT-S BETA
Interventions
None listed
Sponsors
AstraZeneca
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Meet the diagnostic criteria for schizophrenia stated in The Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria. * Subject is hospitalised due to an acute psychotic episode. * Ability of the subject to understand and comply with the requirements of the study, as judged by the investigator.
Exclusion criteria
* Current participation in any clinical trial. * Previous enrolment in the present NIS (in case of recurrence occurred during the enrolment period).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Use of atypical antipsychotic(s) during hospitalisation. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Daily dosage of atypical antipsychotic(s) during hospitalisation. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Mode of administration of atypical antipsychotic(s) during hospitalisation. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Use of psychometric scales in day to day practice in therm of evaluation of the disease symptoms and thus efficacy of the treatment. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Percent of patients with atypical antipsychotic as monotherapy. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Relationship between medication used during the hospitalization and maintenance therapy recommended upon discharge. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Description of the usage of concomitant psychiatric medication (other than atypical antipsychotic) during the hospitalization. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Percent of patients with combinations of antipsychotics. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
| Main criteria of an antipsychotic's selection during hospitalisation expressed as percentage. | Hospitalisation period, an expected average of 3 weeks (variable per patient). | The data will be collected at one visit at the moment of discharge from the hospital. |
Countries
Egypt, Saudi Arabia, United Arab Emirates
Outcome results
None listed